ACT-1014-6470
- Generic Name
- ACT-1014-6470
A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT04608513
- Locations
- 🇩🇪
Parexel International GmbH Klinikum Westend, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath